The strong risk aversion at the FDA is creating at least the perception that it is slowing down or stopping the approval of new, innovative treatments for cancer and other life-threatening terminal diseases.
Expressing concern about FDA's risk aversion impacting treatment approvals.
Share
More from Joe Pitts
The time of 10 o'clock having arrived, I will call this subcommittee meeting to order.
It is unfortunate that we have a Congress of the United States, the majority parties that want to just tear down this law.
Other voices in this conversation
